About Rebiotix
Rebiotix is a company based in Roseville (United States) founded in 2011 was acquired by Ferring Pharmaceuticals in April 2018. Rebiotix has raised $29.3 million across 3 funding rounds from investors including Ferring Pharmaceuticals. Rebiotix offers products and services including Donor Program. Rebiotix operates in a competitive market with competitors including Novozymes, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
- Headquarter Roseville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rebiotix Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.3 M (USD)
in 3 rounds
-
Latest Funding Round
$8.52 M (USD), Series B
Sep 05, 2017
- Investors
-
Employee Count
Not available
-
Acquired by
Ferring Pharmaceuticals
(Apr 05, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rebiotix
Rebiotix offers a comprehensive portfolio of products and services, including Donor Program.
Program for donor-related activities in pharmaceuticals context.
People of Rebiotix
Unlock access to complete
Funding Insights of Rebiotix
Rebiotix has successfully raised a total of $29.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.52 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rebiotix
Rebiotix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ferring Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of drugs in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics
|
Locked | Locked | Locked |
Investor details for Rebiotix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rebiotix
Investment portfolio details for Rebiotix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rebiotix
Detailed financials for Rebiotix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rebiotix Comparisons
Peer comparison for Rebiotix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rebiotix
Rebiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novozymes, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
Detailed competitors of Rebiotix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rebiotix
Complete news archive for Rebiotix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rebiotix
Rebiotix was founded in 2011.
Rebiotix is headquartered in Roseville, United States. It is registered at Roseville, California, United States.
Rebiotix is a funded company, having raised a total of $29.3M across 3 funding rounds to date.
Rebiotix was founded in 2011 and is headquartered in Roseville, United States. Biologic drugs are developed by the company for gastrointestinal diseases, with a focus on recurrent Clostridium difficile infections through microbiome-based approaches. RBX2660, a microbiota suspension derived from fecal transplants, is advanced as a primary therapy. Additional efforts target ulcerative colitis and metabolic syndrome within the biotechnology sector.
Rebiotix's top competitors include Novozymes, Vaxcyte and Serum Institute of India.
Rebiotix offers Donor Program.
Rebiotix has 1 investor. Key investors include Ferring Pharmaceuticals.